Systemic inflammation following cardiopulmonary bypass for mitral valve replacement: the role of non-steroidal anti-inflammatory drugs parecoxib and flurbiprofen

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-PRC-10001046

Enrollment

Unknown

Registered

2010-10-21

Start date

2010-11-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients undergoing mitral balve replacement

Interventions

control:0.9% N.S.

1:inject Flurbiprofen.

2:inject Parecoxib

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. patients undergoing mitral balve replacement2. ASA I-III3. Voluntary to participate the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: Patients with any one of conditions as following: severe hypertension, bleeding diasthesis, peptic ulcer disease, bronchial asthma, cerebrovascular accidents, severe congestive heart failure, chronic inflammatory disease (rheumatoid arthritis, systemic lupus Erythrematosus, Chrohn’s disease, Wegener’s granulomatosis, sarcoidosis, osteoarthritis, chronic obstructive pulmonary disease, ulcerative colitis, psoriasis and multiple sclerosis.

Design outcomes

Primary

Measure	Time frame
IL-6;IL-8;tumor necrosis factor;IL-1;	—

Countries

China

Contacts

Public ContactQingping Wu

wu_qingping1968@yahoo.com.cn+86 13971605283

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026